Economic evaluations from individual-level data are an important component of the process of technology appraisal, with a view to informing resource allocation decisions. A critical problem in these analyses is that both effectiveness and cost data typically present some complexity (e.g. non normality, spikes and missingness) that should be addressed using appropriate methods. However, in routine analyses, simple standardised approaches are typically used, possibly leading to biased inferences. We present a general Bayesian framework that can handle the complexity. We show the benefits of using our approach with a motivating example, the MenSS trial, for which there are spikes at one in the effectiveness and missingness in both outcomes. We contrast a set of increasingly complex models and perform sensitivity analysis to assess the robustness of the conclusions to a range of plausible missingness assumptions. This paper highlights the importance of adopting a comprehensive modelling approach to economic evaluations and the strategic advantages of building these complex models within a Bayesian framework.
Calculating the Expected Value of Sample Information accounting for missing data
Human Technopole(人类技术枢纽);Department of Statistical Science, University College London(伦敦大学学院统计科学系);The Hospital for Sick Children(多伦多多病儿童医院);University of Toronto(多伦多大学)
Identifying expanding TCR clonotypes with a longitudinal Bayesian mixture model and their associations with cancer patient prognosis, metastasis-directed therapy, and VJ gene enrichment
Department of Biostatistics(生物统计系);Department of Radiation Oncology, Mayo Clinic(梅奥诊所放射肿瘤科);Department of Translational Molecular Pathology(转化分子病理学系);Departments of Thoracic/Head and Neck Medical Oncology(胸部/头颈医学肿瘤科);Department of Radiation Oncology, University of Texas MD Anderson Cancer Center(德克萨斯大学安德森癌症中心放射肿瘤科)